secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001437749-25-022877
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica reports positive Phase 2 preeclampsia data: BP reductions, no placental transfer
--------------------------------------------------------------------------------

- DM199 highest dose (Cohort 9, n=3): SBP -35 mmHg (p<0.05), DBP -15 mmHg (p<0.05) at 5 min post-infusion.
- Pooled cohorts 6-9 (n=12) showed sustained BP reductions at 5 min, 30 min, and 24 hours (p≤0.0031).
- No placental transfer; no serious TEAEs; mild nausea (14%), headache (11%), flushing (4%); no discontinuations.
- Uterine artery pulsatility index reduced 13.2% (p=0.0003), indicating improved placental perfusion.
- Study to proceed with dose expansion (Part 1b) and initiate fetal growth restriction cohort (Part 3).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925022877/0001437749-25-022877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925022877/dmtp20250716_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-022877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer